Journal
EPIGENETICS
Volume 6, Issue 8, Pages 1021-1028Publisher
LANDES BIOSCIENCE
DOI: 10.4161/epi.6.8.16064
Keywords
5-aza-2 '-deoxycytidine; decitabine; DNA methyltransferase-1; suicide inactivation; p53; S-phase; cell cycle
Funding
- NCI [5R21CA122270]
- Huntsman Cancer Foundation
- ASCO young investigator award
Ask authors/readers for more resources
5-Aza-2'-deoxycytidine (decitabine) is a drug targeting the epigenetic abnormalities of tumors. The basis for its limited efficacy in solid tumors is unresolved, but may relate to their indolent growth, their p53 genotype or both. We report that the primary molecular mechanism of decitabine-depletion of DNA methyltransferase-1 following its suicide inactivation-is not absolutely associated with cell cycle progression in HCT 116 colon cancer cells, but is associated with their p53 genotype. Control experiments affirmed that the secondary molecular effects of decitabine on global and promoter-specific CpG methylation and MAGE-A1 mRNA expression were S-phase dependent, as expected. Secondary changes in CpG methylation occurred only in growing cells similar to 24-48 h after decitabine treatment; these epigenetic changes coincided with p53 accumulation, an index of DNA damage. Conversely, primary depletion of DNA methyltransferase-1 began immediately after a single exposure to 300 nM decitabine and it progressed to completion within similar to 8 h, even in confluent cells arrested in G(1) and G(2)/M. Our results suggest that DNA repair and remodeling activity in arrested, confluent cells may be sufficient to support the primary molecular action of decitabine, while its secondary, epigenetic effects require cell cycle progression through S-phase.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available